The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human Prokineticin 1.
sELISA: Use at a concentration of 0.25 - 1 µg/ml. Allows the detection of at least 0.2 - 0.4 ng/well of recombinant human Prokineticin 1.
WB: Use at a concentration of 0.1 - 0.2 µg/ml. The detection limit for recombinant human Prokineticin 1 is 1.5 - 3.0 ng/lane, under either reducing or non reducing conditions. Predicted molecular weight: 12 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
Potently contracts gastrointestinal (GI) smooth muscle. Induces proliferation, migration and fenestration (the formation of membrane discontinuities) in capillary endothelial cells derived from endocrine glands. Has little or no effect on a variety of other endothelial and non-endothelial cell types. Induces proliferation and differentiation, but not migration, of enteric neural crest cells. Directly influences neuroblastoma progression by promoting the proliferation and migration of neuroblastoma cells. Positively regulates PTGS2 expression and prostaglandin synthesis. May play a role in placentation. May play a role in normal and pathological testis angiogenesis.
Localizes to glandular epithelium, stroma and vascular epithelial cells of first trimester decidua (at protein level). Up-regulated in first trimester decidua when compared with non-pregnant endometrium. Expressed in the steroidogenic glands, ovary, testis, adrenal and placenta.
Belongs to the AVIT (prokineticin) family.
In adult testis, is strongly expressed only in Leydig cells. In testicular tumors, expressed specifically in Leydig cell tumors (at protein level). Expressed from 14 weeks until birth in fetal testis.